|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To elucidate how CYLD contributes to tumor formation, we aimed to identify molecular partners in keratinocytes.
|
31260673 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In this manuscript we report that the tumor suppressor CYLD, similarly to other renowned tumor suppressor genes, protects from premature aging and cancer.
|
30631004 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These include deletion of the tumor suppressor CYLD, promotor methylation of the Wnt antagonists WIF1, DKK1, DKK3, and sFRP1, sFRP2, sFRP4, sFRP5, as well as overexpression of the co-transcriptional activator BCL9 and the R-spondin receptor LGR4.
|
30770859 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
For this, we explored the tumor microenvironment for targeted drug delivery and synthesized (temperature and pH responsive) double triggered polymeric nanoparticles by the free radical mechanism and characterized them by DLS and TEM.
|
31549130 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
More importantly, the PfL treatment leads to effective inhibition of tumor growth and a ∼2.71 fold increase in the lifespan of EAC mice.
|
31431259 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The tumor suppressor CYLD is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
|
31366726 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The tumor suppressor CYLD is a deubiquitinating enzyme that removes non-degradative ubiquitin linkages bound to a variety of signal transduction adaptors.
|
31067453 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We adopted three different methods: TEM, NTA and western blot analysis to characterize the cell-derived exosomes from NCI-H69 SCLC cell line and normal bronchial epithelial BEAS-2B cell line. we next explored the effects of these exosomes on HUVE cell proliferation and migration in vitro.To verify sFlt-1-loaded exosomes suppress the tumor growth in vivo,we established subcutaneous xenografts in nude mice using the NCI-H69 cell line.
|
31441580 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes.
|
31624251 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
|
29974194 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Interestingly, TEM images of tumor sections show intercellular lysosomal subcellular localization of the GNP-ABPs.
|
30148621 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The sequential delivery vesicles showed the anticipated three-layered TEM structure and dual-convertible (surface charge- and particle size-reversible) features in the tumor environment (pH 6.5), which guaranteed the sequential release of siVEGF-CPPs and PTX in the tumor extracellular environment and tumor cells, respectively.
|
30144476 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Here we show that alternative splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of CD5<sup>+</sup> B cells through sustained canonical NF-κB signaling.
|
28566736 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in the tumour suppressor gene CYLD are recognized to be associated with the development of multiple cutaneous cylindromas.
|
29569226 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These neoplasms also share considerable phenotypic resemblance and co-exist with certain dermal adnexal tumors harboring the CYLD gene mutations inferring common genetic association.
|
29463883 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Patients with germline mutations in a tumour suppressor gene called CYLD develop multiple, disfiguring, hair follicle tumours on the head and neck.
|
28270164 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD lysine 63 deubiquitinase (CYLD) was originally identified as a tumor suppressor that is mutated in familial cylindromatosis.
|
29344161 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
PfLP treatment resulted in tumor growth inhibition and increased the life-span of the EAC bearing mice, without showing any detectable side effects, as revealed by histological parameters.
|
29174033 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the functional consequence of CYLD loss and the mechanism underlying its putative role as a tumor suppressor gene in the pathogenesis of MM has not been established.
|
27775078 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumor suppressor and a deubiquitination enzyme.
|
28840581 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Ten TSGs were up-regulated (FAM123B, RB1, TP53, RUNX1, MSH2, BRCA1, BRCA2, SOX9, NPM1, and RNF43); six TSGs were down-regulated (PAX5, IZKF1, GATA3, PRDM1, TET2, and CYLD); four were associated with MSI tumors (MLH1, PTCH1, and CEBPA down-regulated and MSH6 up-regulated); and two were associated with MSS tumors (PHF6 and ASXL1 up-regulated).
|
28675510 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
This study aims to investigate the possible anticancer activity of two clinically used drugs: a natural antioxidant agent (salicin) and an antihyperlipidemic agent (fenofibrate) against two breast cancer models (in vivo EAC and in vitro MCF7) and the pancreatic cancer cell line (Panc-1).Our results have shown that both salicin and fenofibrate exerted an in vivo anticancer activity as evidenced by the decrease in tumor weight, tumor volume, CEA level, and reduced tumor cholesterol content through an antioxidant (reduced MDA level and increased GSH and catalase content) and an antiinflammatory activity (reduced TNF-∝ level).
|
28733879 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
They are now known to occur on an inherited basis as a result of mutations in the tumor-suppressor gene CYLD.
|
27890238 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a deubiquitinating enzyme that exerts a tumor suppressive function.
|
27570065 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The downregulation of miR21 and miR181b-1 and subsequent activation of PTEN/Akt and CYLD/IκB signaling axis leading to decreased NF-κB activity required to maintain the tumor-inhibiting effect of Rig-G.. Our findings contribute to a better understanding of the antitumor effect mechanism of Rig-G, as well as offer a novel strategy for lung cancer therapy.
|
27602766 |
2016 |